Cardiac Dimensions Appoints Dr. Satya Shreenivas as Chief Medical Officer

January 16, 2024—Cardiac Dimensions, developer of minimally invasive treatments for patients with heart failure with functional mitral regurgitation (FMR), announced that interventional cardiologist Satya Shreenivas, MD, joined the company as Chief Medical Officer.

The company’s Carillon mitral contour system is designed to treat both FMR and heart failure in a simple, short, minimally invasive procedure. It is commercially available for transcatheter mitral valve repair in Europe. The company stated that the device consistently shows favorable left ventricular remodeling while also acutely reducing FMR in clinical trials.

According to the company, Dr. Shreenivas has been instrumental in advising Cardiac Dimensions on its EMPOWER trial of the Carillon mitral contour system.

Dr. Shreenivas led the structural heart program and cardiac catheterization laboratory at the University of Cincinnati and spent several years with The Christ Hospital in Cincinnati, Ohio. He served as an investigator in many high-profile clinical trials, including several significant structural heart studies. Additionally, Dr. Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heart failure, and coronary arenas.

His industry roles have included serving as Chief Medical Officer for HLT Medical, a transcatheter heart valve company; Chief of Cardiology with Optum/United Health subsidiary SCA Health; and Medical Director for the clinical research organization Medpace.

Dr. Shreenivas did his cardiology fellowship training at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. He also received an MBA from the Wharton School at the University of Pennsylvania.

“I’ve seen the compelling clinical evidence on Carillon therapy from Europe and look forward to helping the team expand the supportive body of evidence for this intriguing technology with the United States pivotal EMPOWER trial,” commented Dr. Shreenivas in the company’s press release. “I have always been energized by my work with emerging technologies that fill an unmet clinical need and am excited by the opportunity this therapy presents to enhance the lives of heart failure patients in a way that isn’t possible today.”

Cardiac Dimensions CEO Rick Wypych added, “We are thrilled to welcome Dr. Shreenivas to Cardiac Dimensions and expect his valuable combination of clinical and industry experience, passion for evidence generation, and innovative spirit will benefit the EMPOWER trial studying our Carillon device as a therapy for heart failure patients with FMR. Having a structural heart leader like Satya as a member of the Cardiac Dimensions team will provide us with unique insights for our clinical research, as well as ongoing commercial efforts.”

The Carillon system has received European CE Mark approval for New York Heart Association class II and greater patients and Australian Therapeutic Goods Approval (TGA); it is commercially available in those markets. In the United States, it is an investigational device, advised the company.